Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki, Greece, 22-25 June 2008

International Journal of Antimicrobial Agents

Volumn 33, Issue 2, 2009, Pages 101-104

  Groll, Andreas H ^a   McNeil Grist, Liz ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NONE

Author keywords

Adults; Antifungal prophylaxis; Antifungal treatment; Children; Diagnosis; Immunocompromised hosts; Invasive fungal infections

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

CONFERENCE PAPER; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL STRAIN; GREECE; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; LOADING DRUG DOSE; MYCOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT DURATION;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; RISK FACTORS;

EID: 58149193354     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.08.014     Document Type: Conference Paper

References (32)

1. Morgan J., Wannemuehler K.A., Marr K.A., Hadley S., Kontoyiannis D.P., Walsh T.J., et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 43 Suppl. 1 (2005) S49-58
2. Trick W.E., Fridkin S.K., Edwards J.R., Hajjeh R.A., and Gaynes R.P. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 35 (2002) 627-630
3. Sendid B., Cotteau A., Francois N., D'Haveloose A., Standaert A., Camus D., et al. Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 6 (2006) 80
4. Chamilos G., Marom E.M., Lewis R.E., Lionakis M.S., and Kontoyiannis D.P. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41 (2005) 60-66
5. Upton A., and Marr K.A. Emergence of opportunistic mould infections in the hematopoietic stem cell transplant patient. Curr Infect Dis Rep 8 (2006) 434-441
6. Pagano L., Caira M., Candoni A., Offidani M., Fianchi L., Martino B., et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91 (2006) 1068-1075
7. Groll A.H., Roilides E., and Walsh T.J. Fungal infections in pediatric patients. In: Anaissie E.J., McGinnis M.R., and Pfaller M.A. (Eds). Clinical mycology (2008), Churchill Livingstone, Philadelphia, PA
8. Zaoutis T.E., Heydon K., Chu J.H., Walsh T.J., and Steinbach W.J. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117 (2006) e711-e716
9. Zaoutis T.E., Argon J., Chu J., Berlin J.A., Walsh T.J., and Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41 (2005) 1232-1239
10. Zaoutis T.E., Heydon K., Localio R., Walsh T.J., and Feudtner C. Outcomes attributable to neonatal candidiasis. Clin Infect Dis 44 (2007) 1187-1193
11. Zaoutis T.E., Roilides E., Chiou C.C., Buchanan W.L., Knudsen T.A., Sarkisova T.A., et al. Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 26 (2007) 723-727
12. Greene R.E., Schlamm H.T., Oestmann J.W., et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 44 (2007) 373-379
13. Rickerts V., Mousset S., Lambrecht E., Tintelnot K., Schwerdtfeger R., Presterl E., et al. Comparison of histopathological analysis, culture, and polymerase chain reaction assays to detect invasive mold infections from biopsy specimens. Clin Infect Dis 44 (2007) 1078-1083
14. Marr K.A., Laverdiere M., Gugel A., and Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40 (2005) 1762-1769
15. Hope W.W., Walsh T.J., and Denning D.W. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 5 (2005) 609-622
16. Kami M., Tanaka Y., Kanda Y., Ogawa S., Masumoto T., Ohtomo K., et al. Computed tomographic scan of the chest, latex agglutination test and plasma (1 → 3)-β-d-glucan assay in early diagnosis of invasive pulmonary aspergillosis: a prospective study of 215 patients. Haematologica 85 (2000) 745-752
17. Burgos A., Zaoutis T.E., Dvorak C.C., Hoffman J.A., Knapp K.M., Nania J.J., et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 121 (2008) e1286-e1294
18. Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Med Mycol 44 Suppl. (2006) 199-205
19. Maertens J., Theunissen K., Verhoef G., Verschakelen J., Lagrou K., Verbeken E., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 41 (2005) 1242-1250
20. Herbrecht R., Fluckiger U., Gachot B., Ribaud P., Theibaut A., and Cordonnier C. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Suppl 5 (2007) 49-59
21. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2004) 161-189
22. Walsh T.J., Anaissie E.J., Denning D.W., Herbrecht R., Kontoyiannis D.P., Marr K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 327-360
23. Walsh T.J., Seibel N.L., Arndt C., Harris R.E., Dinuble M.J., Reboli A., et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 18 (1999) 702-708
24. Queiroz-Telles F., Berezin E., Leverger G., Freire A., van der Vyver A., Chatpitayasunondh T., et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27 (2008) 820-826
25. Maertens J., Madero-Lopez L., Reilly A., Lehrnbecher T., Groll A.H., Jafri H., et al. A randomized, double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of pediatric patients with persistent fever and neutropenia. 47th interscience conference on antimicrobial agents and chemotherapy (ICAAC), 17-20 September 2007. Chicago, IL. Washington, DC: ASM Press (2007) Abstract M-621
26. Jafri H., Zaoutis T., Keller N., Huang L., Locatelli F., Ebell W., et al. Prospective, multicenter study of caspofungin (CAS) for the treatment (Rx) of documented fungal infection in pediatric patients (Ped Pts). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27-30 September 2006. San Francisco, CA. Washington, DC: ASM Press (2006) Abstract G-0873a
27. Maertens J.A., Frère P., Lass-Flörl C., Heinz W., and Cornely O.A. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer Suppl 5 (2007) 43-48
28. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356 (2007) 348-359
29. Ullmann A.J., Lipton J.H., Vesole D.H., Chandrasekar P., Langston A., Tarantolo S.R., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356 (2007) 335-347
30. Cornely O., and Ullman A.J. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 46 (2008) 1626-1627
31. Pachl J., Svoboda P., Jacobs F., Vandewoude K., Hoven B., Spronk P., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42 (2006) 1404-1413
32. Cowen L.E., and Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309 (2005) 2185-2189